T22-DITOX-H6

T22-DITOX-H6 is a multivalent protein nanoparticle designed for **targeted cancer therapy**. It comprises three functional domains: - The **T22 peptide ligand** targets and binds the chemokine receptor **CXCR4**, which is commonly overexpressed on certain cancer cells, especially in acute myeloid leukemia (AML). - **DITOX** is a toxin domain derived from *Corynebacterium diphtheriae* (diphtheria toxin), responsible for the drug's potent cytotoxicity by inhibiting protein synthesis and inducing cell death once internalized into target cells. - **H6** (hexahistidine tag) promotes oligomerization, forming nanoparticles that present multiple T22 ligands for increased avidity and selectivity. The drug is selectively internalized into **CXCR4-positive** cells via receptor-mediated endocytosis. After entry, DITOX is released into the cytoplasm, where it inactivates **Eukaryotic elongation factor 2 (eEF-2)**, leading to inhibition of protein synthesis and cancer cell death. This strategy aims to minimize toxicity by restricting cytotoxicity to cancer cells with high CXCR4 expression, such as leukemia stem cells, while sparing normal tissues. T22-DITOX-H6 is under development primarily for **relapsed or refractory AML**, targeting quiescent, chemotherapy-resistant leukemia stem cells. It is also of interest for other CXCR4-high malignancies[1].

Brand names

T22-DITOX-H6T-22-DITOX-H6T 22-DITOX-H6

Other names

T22-DITOX-H6T-22-DITOX-H6T 22-DITOX-H6